Poxviral oncolytic vectors

9,884,080

13/778235

February 27, 2013

The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.

Transgene S.A. (Parc D'Innovation, FR)

Transgene S.A. (Illkirch Graffenstaden)

1. A method for treating tumors in a host organism or cell comprising administering a recombinant poxvirus consisting essentially of: a defective I4L gene and/or a defective F4L gene; and a defective J2R gene, wherein the recombinant poxvirus does not comprise a defective vaccinia growth factor gene, with the proviso that said poxvirus is not NYVAC and that said poxvirus is oncolytic, to said host organism or cell for such period of time as required to elicit the desired effect.

2. A method for reducing cancer in a host organism or cell comprising administering to said host organism or cell for such period of time as required to elicit the desired effect a recombinant poxvirus consisting essentially of: a defective I4L gene and/or a defective F4L gene; and a defective J2R gene, wherein the recombinant poxvirus does not comprise a defective vaccinia growth factor gene, with the proviso that said poxvirus is not NYVAC and that said poxvirus is oncolytic.

3. The method as defined by claim 1 or claim 2 , wherein said poxvirus is administered via the systemic route.

4. The method as defined by claim 1 or claim 2 , further comprising administering a pharmaceutically acceptable quantity of a prodrug to said host organism or cell.

5. The method as defined by claim 1 or claim 2 , further comprising administering a pharmaceutically acceptable quantity of a prodrug to said host organism or cell, wherein the administration of said prodrug takes place at least 3 days after the administration of said poxvirus.

6. The method as defined by claim 1 or claim 2 , further comprising administering a pharmaceutically acceptable quantity of a prodrug to said host organism or cell, wherein the administration of said prodrug takes place at least 7 days after the administration of said poxvirus.

5364773 November 1994 Paoletti et al.
5453364 September 1995 Paoletti et al.
5759553 June 1998 Paoletti et al.
6537594 March 2003 Paoletti et al.
6596533 July 2003 Erbs et al.
7208313 April 2007 McCart
2003/0031681 February 2003 McCart et al.
2005/0112099 May 2005 Berinstein et al.
9-503902 April 1997
WO 90/10693 September 1990
WO 92/15672 September 1992
WO 94/16716 August 1994
WO 2011/003194 January 2011

McCart et al., 2001, J. Cancer Res. 61:8751-8757. cited by examiner
Beaud et al 1995, Biochimie 77:774-779. cited by examiner
Puhlmann et al., 2000, Cancer Gene Therapy 7:66-73. cited by examiner
Thorne et al., 2004, Expert Opin. Biol. Ther. 4:1307-1321. cited by examiner
Ganant et al 1999, Cancer Research 59: 3396-3403. cited by examiner
Howley et al 1996, Gene 172:233-237. cited by examiner
International Search Report issued in corresponding PCT/EP/2008/009720 dated Mar. 17, 2009. cited by applicant
Israeli Office Action from Israeli Patent Application No. 204538 dated Jan. 22, 2012. cited by applicant
Child et al., Insertional Inactivation of the Large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus is Associated with Reduced Virulence in Vivo, 174 Virology 625-629 (1990). cited by applicant
Erbs et al., Modified vaccinia virus Ankara as a vector for suicide gene therapy, 15(1) Cancer Gene Therapy 18-28 (Jan. 2008; e-published Nov. 9, 2007) (Abstract). cited by applicant
Guse et al., Oncolytic vaccinia virus for the treatment of cancer, Informa Healthcare (Rightline) 1-14 (2011). cited by applicant
Howley et al., A vaccinia virus transfer vector using a GUS reporter gene inserted into the I4L locus, 172 Gene 233-237 (1996). cited by applicant
Jourdier et al., Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2), 10(26) Gene Therapy 2126-2132 (Dec. 2003) (Abstract). cited by applicant
Najera et al., Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVS and NYVAC) and role for the C7L Gene, 80(12) Journal of Virology 6033-6047 (Jun. 2006). cited by applicant
Perkus et al., Deletion of 55 Open Reading Frames from the Termini of Vaccinia Virus, 180 Virology 406-410 (1991). cited by applicant
Sivanandham et al., Colon cancer cell vaccine prepared with replication-deficient vaccinia virus encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice, 46(5) Cancer Immunol Immunother 261-267 (Jul. 1998) (Abstract). cited by applicant
Studebaker et al., Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy, 1(1) Drug Design Reviews 1-13 (2004). cited by applicant
Office Action dated Apr. 17, 2013, in corresponding Chinese Patent Application No. 201210160650.3, and partial English translation. cited by applicant
Thorne et al., Vaccinia virus and oncolytic virotherapy of cancer, 7(4) Curr Opin Mol Ther 359-365 (2005). cited by applicant
Notification of Reason for Rejection dated Aug. 16, 2013, in corresponding Japanese Patent Application No. 2010-533510. cited by applicant
Goebel et al., The Complete DNA Sequence of Vaccinia Virus, 179 Virology 247-266 (1990). cited by applicant
Zhang et al., Eradication of Solid Human Breast Tumors in Nude Mice with Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus, 67(20) Cancer Research 10038-10046 (2007). cited by applicant
English Translation of an Official Action issued May 23, 2016, in Israeli Patent Application No. 220653. cited by applicant

edspgr.09884080